190 related articles for article (PubMed ID: 25403717)
1. A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening.
Cadman L; Wilkes S; Mansour D; Austin J; Ashdown-Barr L; Edwards R; Kleeman M; Szarewski A
J Med Screen; 2015 Mar; 22(1):28-37. PubMed ID: 25403717
[TBL] [Abstract][Full Text] [Related]
2. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial.
Szarewski A; Cadman L; Mesher D; Austin J; Ashdown-Barr L; Edwards R; Lyons D; Walker J; Christison J; Frater A; Waller J
Br J Cancer; 2011 Mar; 104(6):915-20. PubMed ID: 21343937
[TBL] [Abstract][Full Text] [Related]
3. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study.
Gök M; Heideman DA; van Kemenade FJ; Berkhof J; Rozendaal L; Spruyt JW; Voorhorst F; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
BMJ; 2010 Mar; 340():c1040. PubMed ID: 20223872
[TBL] [Abstract][Full Text] [Related]
4. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
5. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial.
Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
BMC Cancer; 2018 Mar; 18(1):273. PubMed ID: 29523108
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
7. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
8. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ
Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569
[TBL] [Abstract][Full Text] [Related]
9. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
Arbyn M; Smith SB; Temin S; Sultana F; Castle P;
BMJ; 2018 Dec; 363():k4823. PubMed ID: 30518635
[TBL] [Abstract][Full Text] [Related]
10. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
11. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program.
Gök M; van Kemenade FJ; Heideman DA; Berkhof J; Rozendaal L; Spruyt JW; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
Int J Cancer; 2012 Mar; 130(5):1128-35. PubMed ID: 21484793
[TBL] [Abstract][Full Text] [Related]
12. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
[TBL] [Abstract][Full Text] [Related]
14. Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.
Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
BMC Cancer; 2016 Nov; 16(1):835. PubMed ID: 27809810
[TBL] [Abstract][Full Text] [Related]
15. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
[TBL] [Abstract][Full Text] [Related]
16. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.
Agorastos T; Chatzistamatiou K; Tsertanidou A; Mouchtaropoulou E; Pasentsis K; Kitsou A; Moysiadis T; Moschaki V; Skenderi A; Katsiki E; Aggelidou S; Venizelos I; Ntoula M; Daponte A; Vanakara P; Garas A; Stefos T; Vrekoussis T; Lymberis V; Kontomanolis EN; Makrigiannakis A; Manidakis G; Deligeoroglou E; Panoskaltsis T; Decavalas GO; Michail G; Kalogiannidis I; Koukoulis G; Zempili P; Halatsi D; Truva T; Piha V; Agelena G; Chronopoulou A; Vaitsi V; Chatzaki E; Paschopoulos M; Adonakis G; Kaufmann AM; Hadzidimitriou A; Stamatopoulos K
Cancer Prev Res (Phila); 2019 Oct; 12(10):701-710. PubMed ID: 31427275
[TBL] [Abstract][Full Text] [Related]
17. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
19. Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women's own preferred test method into account-A Swedish randomised controlled trial.
Lilliecreutz C; Karlsson H; Spetz Holm AC
PLoS One; 2020; 15(7):e0235202. PubMed ID: 32614875
[TBL] [Abstract][Full Text] [Related]
20. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
